ReviewPharmacoEconomics2023

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Antoinette D I van Asselt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.